Guardant Health stock declines amid market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Should l Buy GH?
Guardant Health Inc's stock fell by 6.50% as it crossed below its 5-day SMA, reflecting a challenging trading environment.
The decline in Guardant Health's stock price comes amid broader market weakness, with the Nasdaq-100 down 0.97% and the S&P 500 down 0.54%. This suggests a sector rotation, as investors may be reallocating their portfolios away from healthcare stocks in response to market conditions.
As the market continues to fluctuate, Guardant Health may face further pressure unless there are positive developments or shifts in investor sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GH
Wall Street analysts forecast GH stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 87.080
Low
105.00
Averages
124.69
High
155.00
Current: 87.080
Low
105.00
Averages
124.69
High
155.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Verana Health Partners with Guardant Health to Enhance Cancer Therapy Development
- Data Integration Advantage: The partnership between Verana Health and Guardant Health combines high-quality EHR data with genomic data, enabling biopharmaceutical researchers to better understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies and enhancing patient care quality.
- Enhanced Clinical Insights: By integrating NMIBC EHR data with genomic data, researchers can more accurately assess patient risk and optimize treatment choices, particularly regarding the applicability of BCG therapy, which improves treatment efficacy and patient satisfaction.
- Market Coverage Expansion: This collaboration extends Verana Health's cancer care data to solid tumors such as lung, breast, and colorectal cancers, enhancing the diversity of the dataset and clinical insights, allowing it to serve 17 of the top 20 global biopharma companies.
- Regulatory Collaboration Strengthening: The combined regulatory expertise of both companies positions them as a top-tier partner for close collaboration with the FDA, further solidifying Verana Health's standing in the biopharma industry and accelerating the implementation of clinical trial solutions.
See More
Verana Health Partners with Guardant Health to Enhance Oncology Research
- Data Integration Enhances Research Efficiency: The partnership between Verana Health and Guardant Health integrates high-quality EHR data with genomic data, enabling biopharmaceutical researchers to more rapidly understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies.
- Enhanced Clinical Insights: By combining NMIBC EHR data with genomic data, researchers can better select treatment options and optimize decision-making for non-muscle invasive bladder cancer patients, ultimately improving patient treatment outcomes.
- Expanded Patient Coverage: This collaboration allows Verana Health to cover over 10 million oncology patients and establishes strong ties with 17 of the top 20 global biopharma companies, enhancing its influence within the biopharma industry.
- Regulatory Collaboration Advantage: The combined regulatory expertise of both companies positions them as a top-tier partner for FDA collaborations, further driving the acceleration of clinical trial solutions and improving R&D efficiency in the life sciences sector.
See More
U.S.-Iran Conflict Triggers Volatility in Healthcare Stocks
- Oversold Condition: The ongoing U.S.-Iran conflict has led to oversold conditions in the healthcare sector, with Ionis Pharmaceuticals (IONS) experiencing a 12.27% decline over the past 15 days, indicating heightened market concerns.
- Key Stock Performance: Guardant Health (GH) and Dexcom (DXCM) fell by 8.96% and 12.52%, respectively, while Humana (HUM) dropped 13.18%, reflecting significant selling pressure across the healthcare stocks amid market volatility.
- Market Sentiment Analysis: Although oversold conditions typically signal heavy selling pressure, the potential for short-term rebounds exists if fundamentals remain intact, presenting possible buying opportunities for investors.
- Industry Outlook: With the broad pullback in healthcare stocks, market analysts suggest focusing on sector rotation opportunities, particularly in the Healthcare XLV index, which may become the next focal point for investors.
See More
Guardant Health Partners with Manulife to Launch Multi-Cancer Detection Test in Asia
- First Multi-Cancer Detection Test: Guardant Health launches the Shield™ multi-cancer detection test in Hong Kong, Singapore, and the Philippines, set to be available for eligible Manulife customers starting April 2026, marking a significant advancement in early cancer detection in the region.
- Broad Detection Range: The test screens for 10 common cancers, including bladder, colorectal, and breast cancer, using a single blood draw, specifically targeting individuals aged 45 and older at average risk, aiming to increase screening participation and reduce cancer mortality rates.
- Innovative Partnership Model: The collaboration with Manulife represents the first partnership with a major insurer in Asia, aimed at addressing unmet health needs through innovative technologies, showcasing Guardant Health's strategic commitment to advancing early cancer detection.
- Significant Market Potential: With cancer being a leading cause of death in Asia, the introduction of the Shield MCD test not only enhances customer health management awareness but also has the potential to significantly improve survival rates through early detection, driving growth for the company in the Asia-Pacific market.
See More
Stock Market Movers: Opendoor, Nvidia, Grail, Newmont, AppLovin, and Others
- Market Outlook: Stock futures are indicating potential gains on Friday.
- Investor Sentiment: Investors are overlooking rising oil prices.
- Focus on Inflation: Attention is shifting towards upcoming key inflation data.
- Economic Indicators: The market's reaction suggests optimism despite external pressures.
See More
Guardant Health Launches Colorectal Cancer Screening Grant Program
- Grant Program Launch: Guardant Health has announced the initiation of its Community Colorectal Cancer Screening Grant Program, aimed at supporting community organizations in expanding screening access during March's Colorectal Cancer Awareness Month, with up to 100 Shield tests provided per selected organization to enhance screening participation.
- No-Cost Testing: All Shield tests will be provided at no cost to patients and participating organizations, a move that not only alleviates financial burdens but also promotes health equity by removing barriers to screening in underserved and underscreened communities.
- Innovative Screening Tool: The Shield test is the first blood-based screening option for colorectal cancer approved by the FDA, intended for adults aged 45 and older at average risk, offering a more convenient screening alternative designed to increase acceptance and participation rates.
- Application Deadline: Interested organizations must submit their applications by February 17, 2026, with approval notifications sent via email on February 20, reflecting the company's commitment to supporting community health advocacy and outreach efforts.
See More
Verana Health Partners with Guardant Health to Enhance Cancer Therapy Development
- Data Integration Advantage: The partnership between Verana Health and Guardant Health combines high-quality EHR data with genomic data, enabling biopharmaceutical researchers to better understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies and enhancing patient care quality.
- Enhanced Clinical Insights: By integrating NMIBC EHR data with genomic data, researchers can more accurately assess patient risk and optimize treatment choices, particularly regarding the applicability of BCG therapy, which improves treatment efficacy and patient satisfaction.
- Market Coverage Expansion: This collaboration extends Verana Health's cancer care data to solid tumors such as lung, breast, and colorectal cancers, enhancing the diversity of the dataset and clinical insights, allowing it to serve 17 of the top 20 global biopharma companies.
- Regulatory Collaboration Strengthening: The combined regulatory expertise of both companies positions them as a top-tier partner for close collaboration with the FDA, further solidifying Verana Health's standing in the biopharma industry and accelerating the implementation of clinical trial solutions.
See More
Verana Health Partners with Guardant Health to Enhance Oncology Research
- Data Integration Enhances Research Efficiency: The partnership between Verana Health and Guardant Health integrates high-quality EHR data with genomic data, enabling biopharmaceutical researchers to more rapidly understand the correlations between molecular biomarkers and clinical outcomes, thereby accelerating the development of new therapies.
- Enhanced Clinical Insights: By combining NMIBC EHR data with genomic data, researchers can better select treatment options and optimize decision-making for non-muscle invasive bladder cancer patients, ultimately improving patient treatment outcomes.
- Expanded Patient Coverage: This collaboration allows Verana Health to cover over 10 million oncology patients and establishes strong ties with 17 of the top 20 global biopharma companies, enhancing its influence within the biopharma industry.
- Regulatory Collaboration Advantage: The combined regulatory expertise of both companies positions them as a top-tier partner for FDA collaborations, further driving the acceleration of clinical trial solutions and improving R&D efficiency in the life sciences sector.
See More
U.S.-Iran Conflict Triggers Volatility in Healthcare Stocks
- Oversold Condition: The ongoing U.S.-Iran conflict has led to oversold conditions in the healthcare sector, with Ionis Pharmaceuticals (IONS) experiencing a 12.27% decline over the past 15 days, indicating heightened market concerns.
- Key Stock Performance: Guardant Health (GH) and Dexcom (DXCM) fell by 8.96% and 12.52%, respectively, while Humana (HUM) dropped 13.18%, reflecting significant selling pressure across the healthcare stocks amid market volatility.
- Market Sentiment Analysis: Although oversold conditions typically signal heavy selling pressure, the potential for short-term rebounds exists if fundamentals remain intact, presenting possible buying opportunities for investors.
- Industry Outlook: With the broad pullback in healthcare stocks, market analysts suggest focusing on sector rotation opportunities, particularly in the Healthcare XLV index, which may become the next focal point for investors.
See More
Guardant Health Partners with Manulife to Launch Multi-Cancer Detection Test in Asia
- First Multi-Cancer Detection Test: Guardant Health launches the Shield™ multi-cancer detection test in Hong Kong, Singapore, and the Philippines, set to be available for eligible Manulife customers starting April 2026, marking a significant advancement in early cancer detection in the region.
- Broad Detection Range: The test screens for 10 common cancers, including bladder, colorectal, and breast cancer, using a single blood draw, specifically targeting individuals aged 45 and older at average risk, aiming to increase screening participation and reduce cancer mortality rates.
- Innovative Partnership Model: The collaboration with Manulife represents the first partnership with a major insurer in Asia, aimed at addressing unmet health needs through innovative technologies, showcasing Guardant Health's strategic commitment to advancing early cancer detection.
- Significant Market Potential: With cancer being a leading cause of death in Asia, the introduction of the Shield MCD test not only enhances customer health management awareness but also has the potential to significantly improve survival rates through early detection, driving growth for the company in the Asia-Pacific market.
See More
Stock Market Movers: Opendoor, Nvidia, Grail, Newmont, AppLovin, and Others
- Market Outlook: Stock futures are indicating potential gains on Friday.
- Investor Sentiment: Investors are overlooking rising oil prices.
- Focus on Inflation: Attention is shifting towards upcoming key inflation data.
- Economic Indicators: The market's reaction suggests optimism despite external pressures.
See More
Guardant Health Launches Colorectal Cancer Screening Grant Program
- Grant Program Launch: Guardant Health has announced the initiation of its Community Colorectal Cancer Screening Grant Program, aimed at supporting community organizations in expanding screening access during March's Colorectal Cancer Awareness Month, with up to 100 Shield tests provided per selected organization to enhance screening participation.
- No-Cost Testing: All Shield tests will be provided at no cost to patients and participating organizations, a move that not only alleviates financial burdens but also promotes health equity by removing barriers to screening in underserved and underscreened communities.
- Innovative Screening Tool: The Shield test is the first blood-based screening option for colorectal cancer approved by the FDA, intended for adults aged 45 and older at average risk, offering a more convenient screening alternative designed to increase acceptance and participation rates.
- Application Deadline: Interested organizations must submit their applications by February 17, 2026, with approval notifications sent via email on February 20, reflecting the company's commitment to supporting community health advocacy and outreach efforts.
See More
